Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
August 5, 2025
The Alzheimer’s Association International Conference (AAIC) Toronto July 27-31 2025
AAIC Session July 30, 2025
“Network alterations and aberrant neuronal activity in Alzheimer’s disease: novel targets to understand and influence disease progression”
Our presentation within this scientific session focused on AD biomarker findings in AgeneBio’s HOPE4MCI clinical trial. AgeneBio’s presentation also announced the development of novel GABA alpha5 PAMS to optimally target the condition of neuronal hyperactivity in prodromal AD (and other neurological and psychiatric indications) as a novel therapeutic. The targeting of neuronal hyperactivity is now a significant focus for therapeutic development in the AD field.
